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The Use of Ferrokinetics in the Study of
Experimental Anemia
by Eun Woo Lee,* James J. Kocsis,t and
Robert Snydert
Erythropoietic cells in bone marrow are vulnerable to cytotoxic substances. There are three
types of erythroid precursors: cells that can take up Fe but do not proliferate (reticulocytes),
those that can take up Fe and proliferate (normoblasts and pronormoblasts), and those cells
that do not take up Fe but can proliferate and differentiate into the erythroid cell line (ERC
and stem cells). Each ofthese erythroid precursors requires a certain time before they emerge
into the peripheral blood as mature red blood cells. By applying our understanding of
ferrokinetics associated with erythropoiesis, it was possible to estimate a cytotoxic effect of
chemicals on proliferating erythroid precursors (pronormoblasts) in mice by measuring 24-hr
59Fe uptake in red blood cells 48 hr after treatment with chemicals. The effect ofchemicals on
pluripotent hemopoietic stem cells in mice was also estimated by measuring 24-hr 59Fe uptake
72 hr after treatment with chemicals. The validity of experimental schemes was tested using
cytarabine, methotrexate, vinblastine, cyclophosphamide, and busulfan, which are known to
act against specific cell types. Effects on pluripotent hemopoietic stem cells were tested with or
without activation ofstem cells in G, into cell cycle. Applications ofthe 59Fe uptake method in
the study of (1) benzene toxicity and (2) effect of pentobarbital on the toxic action of
hydroxyurea and cytarabine are described. Proper application of the ferrokinetic characteris-
tics of erythropoietic cells enables the establishment of a methodology which can be used to
evaluate potential toxic effects of chemicals on erythroid precursor cells and pluripotent
hemopoietic stem cells.
Introduction
Bone marrow, a dynamic system which produces
blood cells, is vulnerable to cytotoxic agents. The
erythropoietic system retains several characteris-
tics that allow for a rather precise experimental
evaluation of the system: the response of early
erythroid precursor cells to erythropoietin, the
capability of erythroid cells to synthesize hemoglo-
bin, and the existance of a histochemical marker for
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reticulocytes. By using ferrokinetic features and
other developmental characteristics of cells invol-
ved in erythropoiesis, it was possible to measure
the relative size of a cellular pool of different
erythroid precursor cells affected by chemical ag-
ents. We believe such a methodology can be used
for an assessment of hazard caused by cytotoxic
agents onerythropoietic cells includinghemopoietic
stem cells.
This presentation will discuss: ferrokinetics in-
volved in erythropoiesis, rationale in the applica-
tion of ferrokinetics for evaluating chemically in-
ducederythropoietictoxicity, anexperimentalscheme
and test for the rationale, and application of the
59Fe uptake method for the assessment ofpotential
erythropoietic toxins.
29Ferrokinetics Involved in
Erythropoiesis
The earliest erythropoietic cell that can be rec-
ognized morphologically is pronormoblast. This cell
is derived from the erythropoietin response cell
(ERC), and the ERC is derived from pluripotent
hemopoietic stem cells. There is evidence that
pluripotent hemopoietic stem cells are the progeny
of more primitive hemopoietic stem cells (1-4).
Pronormoblasts differentiate and mature sequen-
tially into normoblasts, reticulocytes, and erythro-
cytes (Fig. 1). All cells from the ERC to the
normoblast are in cell cycle and thus proliferate (5,
6) while reticulocytes and erythrocytes do not. In
rodents, most pluripotent hemopoietic stem cells
(90-95%) are not in cycle; i.e., they are in Go state
(7, 8), but they can be activated into cell-cycle upon
specific physiological stimuli (9-11). Under normal
conditions, only 5-10% ofstem cells are in cell cycle,
and these constitute the ERC pool. The cells from
pronormoblasts to reticulocytes can synthesize he-
moglobin (6). Therefore, they can take up 59Fe, but
stem cells and ERC do not take up Fe because they
do not make hemoglobin. Thus, from the ferrokin-
etic point ofview, the cells involved in erythropoie-
sis can be classified into three categories: cells that
take up Fe but do not proliferate (reticulocytes),
cells that take up Fe and proliferate (normoblasts
and pronormoblasts), and finally, cells that do not
take up Fe but can proliferate and differentiate into
the erythroid cell line, i.e., ERC and stem cells.
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Rationale for the Application of
Ferrokinetics for Evaluating
Chemically Induced Erythropoietic
Toxicity
The time required for each of the erythrocyte
precursor cells to mature and to be released into
the circulating blood has been determined in mice.
The turnover time of reticulocytes and the genera-
tion times of both pronormoblasts and normoblasts
are about 24 hr (12-15). In these studies, it was
decided that the size of the reticulocyte pool would
be used as a measure of the effects of chemicals on
each ofthe earlier cell types by administering 59Fe,
which rapidly disappears from the circulation, and
sampling the peripheral blood for 59Fe uptake 24 hr
later, a time at which the label in the blood
represents incorporation of the iron into hemoglo-
bin during the period when maturation and release
of the cells into the circulation occurs. Therefore,
the cytotoxic effect of an agent on normoblasts in
mice can be evaluated by giving 59Fe when the
affected erythroid precursors mature to the stage
ofreticulocytes, i.e., 24 hr after treatment with the
agent and by measuring the amount of 59Fe in the
circulating red blood cells 24 hr after giving 59Fe, a
time interval which allows the bone marrow reticu-
locytes to be released into the blood (Fig. 1). The
time when 59Fe is injected as opposed to the time
when the blood sample is taken is the time when the
size ofthe reticulocyte compartment is measured in
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FIGURE 1. Developmental sequences of cells involved in erythropoiesis experimental scheme for
determining the effect ofagent on each cellular compartment: (a) proliferating cells; (b) nonproliferating
cells but can be activated to proliferating cells; (c) nonproliferating mature cells.
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59Fethis scheme because 59Fe is taken up by reticulo-
cytes at the time of 59Fe injection. By the same
token, the effect of agents that damage the pro-
normoblasts can be reflected by the 24 hr '9Fe
uptake value which is measured 48 hr after treat-
ment with the agent.
It has also been shown that it takes 24 hr for the
ERC to differentiate into pronormoblasts (12).
Regarding stem cells, there is no information on the
time required for the cells to differentiate into
ERC. However, our experimental data, which will
be discussed shortly, suggest that stem cells differ-
entiate into ERC immediately upon physiological
stimulus. Thus, we suggest that the effect ofagents
that inhibit pluripotent hemopoietic stem cells and
ERC can be seen when 59Fe is given 72 hr after
treatment with the agent and 24 hr 59Fe uptake is
measured.
Experimental Scheme and Tests
In order to test the validity of the rationale,
three types of cytotoxic agents, for which the
mechanism ofaction is known, were chosen. Metho-
trexate and cytarabine are S-phase specific cyto-
toxic agents and can kill only proliferating cells
(16-22), while cyclophosphamide and busulfan are
cell-cycle stage nonspecific agents and can kill both
proliferating and nonproliferating cells such as
hemopoietic stem cells (23-26). Vinblastine pro-
duces both metaphase arrest of mitosis and some
damage to hemopoietic stem cells (23, 27). The
effect of these cytotoxic agents on each compart-
ment oferythroid precursors were determined by
the 24-hr 5 Fe uptake measured 24, 48, 72, and 96
hr after injection of a single dose of the agent.
Cytarabine and methotrexate lowered 5 Fe up-
take 24 and 48 hr after treatment with the agent,
respectively, as expected, but at 72 and 96 hr 59Fe
uptake was increased over control values (Fig. 2).
An interpretation ofthe overshoot may be that the
ERC pool was immediately replaced by an exces-
sive number of pluripotent stem cells as a compen-
satory mechanism when cytarabine and methotrex-
ate killed the proliferating ERC, pronormoblasts,
and normoblasts (28). An alternative explanation
could be that more cell divisions might be inserted
in the pronormoblast and normoblast compartments
by a shortening of the intermitotic time (29).
However, this latter process cannot be the reason
for the overshoot because 59Fe is given after the
cells of the maturing compartments have already
been released into the blood. Thus, the overshoot
indicates that the ERC pool was immediately
replaced by an excessive number of stem cells.
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Otherwise, a reduction of the 59Fe uptake value
should have been observed when it was measured
72 hr after treatment with methotrexate or cytar-
abine because they kill ERC. Cyclophosphamide
and bulsulfan reduced 59Fe uptake at all times, as
expected, confirming that the action of cell-cycle
stage nonspecific agents on nonproliferating stem
cells can be measured by the 59Fe uptake method.
Vinblastine reduced the 59Fe uptake at both 24 and
48 hr and also less severely at 72 hr, as expected.
Here again, the 59Fe uptake at 96 hr after vinblas-
tine exceeded the control value, suggestingthat the
damage on erythropoietic system activated G( stem
cells into cell cycle.
The fact that the 24-hr V9Fe uptake measured 72
hr after treatment with cytotoxic agents reflects
the effect of the agents on the stem cell compart-
ment is further supported by the following experi-
ments. Three doses of50 mg/kg ofcytarabine were
given every 2 hr over a 4-hr period and 24-hr 59Fe
uptake was measured 72 hr after the last dose of
cytarabine. Under these conditions, the 59Fe up-
take was not affected (Table 1). However, when a
primary dose of 50 mg/kg of cytarabine was given
12 hr prior to the same series of three doses of 50
mg/kg at 2-hr intervals and 24-hr 59Fe uptake was
measured 72 hr after the last dose, a significant
reduction of59Fe uptake by 65% was produced. On
the basis of the spleen colony forming unit assay
(GFU-S) (30), it has been shown that pluripotent
stem cells in the Go state can be induced to
synthesize DNA and divide by cytarabine (10, 31).
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FIGURE 2. Twenty-four hour 59Fe uptake in mice measured at
different time intervals following a single IP dose ofcytarab-
ine (150 mg/kg), methotrexate (20 mg/kg), vinblastine (2
mg/kg), cyclophosphamide (200mg/kg), and asinglesc doseof
busulfan (320 mg/kg). Values represent the mean of 10 mice
per group and were significantly different in all cases except
those at 24 hr after busulfan, 72 hr after methotrexate, and
96 hrafter cytarabine; 72 hraftercytarabine and also at 96 hr
after methotrexate and vinblastine the significance of the
differences was p < 0.05 whereas in all other cases the
differences were p < 0.001.
31Thus, the reduction of 59Fe uptake following a
primary dose of cytarabine, but no reduction with-
out the primary dose, further supports the notion
that the 24-hr 59Fe uptake measured 72 hr after
treatment with cytotoxic agent reflects the effects
of agents on nonproliferating pluripotent stem
cells.
Application of the 59Fe Uptake
Method for the Assessment of
Potential Erythropoietic Toxins
Erythropoietic Toxicity of Benzene
Measured by the 59Fe Uptake Method
Effect of a single subcutaneous dose of benzene
(88, 440, and 2200 mg/kg as a 50% benzene-olive oil
solution) in mice was evaluated by parameters such
as erythrocyte 59Fe uptake, total leukocyte counts
and hematocrits 24 hr after benzene administra-
tion. To determine the 59Fe uptake, mice were
given 59Fe (0.5 ,uCi, 20-40 ng of iron) as ferrous
citrate 24 hrafter benzene treatment and bled 24 hr
later. Unless specified, 59Fe was injected IP through-
out the study. Blood (0.2 ml) from each mouse was
counted in a scintillation well counter and the
percentage of the 59Fe taken up into erythrocytes
was calculated, assuming a blood volume of 6% of
the body weight. Statistical significance was de-
termined by means of Student's t test. Experimen-
tal results in Table 2 indicate that the 59Fe uptake
measurement is a more sensitive method than total
leukocyte counts and hematocrits for evaluating
bone marrow activity.
The stage oferythroid cell development sensitive
to benzene was evaluated using the 59Fe uptake
method. Mice were given single doses ofbenzene sc
and its effect on 59Fe uptake was evaluated after
five specific time intervals (Fig. 3). No suppression
was found after 1 and 12 hr and also 72 hr, whereas
dose-dependent inhibition of the 59Fe uptake was
observed 24 hr and 48 hr after treatment with 440
or 2200 mg/kgdose. Thus, the data can be interpre-
ted to suggest that (1) benzene did not interfere
with an incorporation ofiron into heme, (2) benzene
interfered with proliferation of normoblasts and
pronormoblasts, and (3) benzene did not damage
hemopoietic stem cells which were inthe Go state at
the time of benzene injection.
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FIGURE 3. Effect ofbenzene on24-hrerythrocyte utilization in
mice measured at different time intervals following a single
sc dose of benzene as a 50% (v/v) benzene-olive oil solution:
88, 400, and 2200 mg/kg. Control group received olive oil
only. Values represent the mean of more than 11 mice per
group (11 to 26); (a) significantly different from control (p <
0.001); (b) significantly different from 440 mg/kg dose (p <
0.01).
The effect of toluene on benzene toxicity and
metabolism was also studied by using the 59Fe
uptake method. [3H]Benzene was given subcutan-
eously (SC) at a dose of 440 or 880 mg/kg and the
metabolites in urine were measured over a 24 hr
periodwith orwithout toluene (1720mg/kg, SC). At
48 hr after giving benzene, 59Fe was administered
to determine the degree ofbenzene toxicity. Table
3 shows that toluene reduced the appearance of
benzene metabolites in the urine to 30-44% of
controls. Toluene did not affect 59Fe uptake but did
alleviate the reduction in 59Fe uptake caused by
benzene. Taken together, these results suggest
that inhibition of benzene metabolism was accom-
panied by alleviation or prevention of benzene
toxicity and that benzene toxicity was probably
Table 1. Effect of dose schedules of cytarabine on 59Fe uptake in mice.
24 hr 59Fe uptake measured
Total dose of 72 hr after cytarabine
cytarabine, mg/kg Schedule of administration (mean ± SD), %a
Saline control Three times, 0.2 ml every 2 hr 22.6 ± 7.6 (8)
150 Three times, 50 mg/kg every 2 hr 23.2 ± 8.0 (10)
300 Single injection 29.0 ± 10.6 (9)
200 Initial dose, 50 mg/kg 12 hr prior to three successive doses of 7.8 ± 6.1b (6)
50 mg/kg every 2 hr
aNumber of animals given in parentheses.
bSignificantly lower than control values (p < 0.001).
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72Table 2. Effect of a single dose of benzene on rbc 59Fe utilization, total leukocyte, and hematocrit in mice.
24-hr 59Fe utilization, % Total leukocyte/mm'
Hematocrit
Benzene dose, mg/kg Mean ± SDa CVb Mean ± SDa CVb Mean ± SDa
Olive oil control 24.3 ± 4.8 (14)b 19.8 5991 ± 2492 (16) 42 46 ± 3.8 (16)
88 24.7 ± 6.1 (19) 28.7 5540 ± 2519 (15) 45 45 ± 6.7(15)
440 17.8 ± 3.7c (19) 20.8 4661 ± 1633 (14) 35 47 ± 2.6 (14)
2200 12.1 ± 4.5c (15) 37.2 4585 ± 1551 (17) 34 46 ± 3.9 (17)
aNumber of animals given in parentheses.
bCV = coefficient of variation (standard deviation/mean x 100).
cSignificantly lower than the value of control group (p < 0.001).
caused by a toxic metabolite of benzene. The rocytes was calculated assuming a blood volume of
implication ofbenzene metabolites in benzene toxic- 6% of the body weight.
ity is further described in review articles (33, 34). Sham-operated and partially hepatectomized con-
The liver is generally accepted as the major site trol rats showed no difference in 59Fe uptake,
ofbenzene metabolism. Thus, the role ofthe liverin indicating that partial hepatectomy itself had no
producing benzene-induced bone marrow depres- effect on 9Fe uptake. Benzenereduced 59Fe uptake
sion was investigated using partially hepatectom- to about halfofthe control values in sham-operated
ized rats. Partial hepatectomy (35) resulted in animals (Table 4). No reduction in 59Fe uptake,
removal of 75 + 8% (16 rats) of the liver. Sham however, was observed in the benzene-treated
operations were performed by making a middle partially hepatectomized rats, showing that partial
incision reaching 1-1.5 cm posteriorly from the hepatectomy protected the rat against benzene-
xiphoid process of the sternum, exposing the me- induced bone marrow depression. On the other
dian and left lateral lobes of the liver, and then hand, partial hepatectomy markedly reduced ben-
closing the area with no liver excision. A single zene metabolism, confirming the requirement for
dose ofbenzene (2200 mg/kg) was injected SC 8 hr the production of a metabolite which mediates
after surgery. Generally, labeled [3H]benzene (ap- benzene toxicity.
proximately 80,000 dpm/lxmole) was administered
to determine benzene metabolites in urine (36 hr E cumulative urinary radioactivity). Total radioactiv- Effect of Pentobarbital on the Action
ity in urine was reported as benzene equivalents in of Cytarabine and Hydroxyurea to
,umoles. To determine radioiron utilization, 59Fe Hemopoietic Cells Measured by the 59Fe
(1.0 ,uCi per rat) was injected IP 48 hr after Uptake Method
benzene administration and sample blood was col-
lected 24 hours after 59Fe administration for analy- Since it has been reported that some hypnotics
sis. The percentage of59Fe incorporated into eryth- protectedhemopoietic toxicitycausedbyx-irradiation
Table 3. Effects of toluene on benzene metabolism and on "9Fe uptake in the mouse.
["H] Benzene metabolism/24 hr, % of 24 hr;9Fe Utilization, % of
Treatment administered dose (mean ± SD)W administered dose (mean ± SD)a,b
Control 24.2 ± 4.7 (27)
Toluene (1720 mg/kg) 23.3 ± 4.6 (25)
Benzene (440 mg/kg) 35.8 ± 1.1 (2)C 15.7 ± 4.8" (21)
Benzene and toluene 10.9 ± 7.5 (2)" 22.0 ± 5.9e (28)
Control 18.8 ± 6.2 (22)
Toluene (1720 mg/kg) 15.8 ± 5.5 (19)
Benzene (880 mg/kg) 22.6 ± 5.7 (17) 4.9 ± 3.4'l (19)
Benzene and toluene 9.9 ± 3.9 (17) 9.9 ± 4.5e (17)
aNumber of mice given in parentheses.
b9Fe was injected 48 hr after benzene or toluene administration.
cTwo groups of animals, three animals per group.
dSignificantly different from both control and toluene groups (p < 0.05).
eSignificantly different from group receiving benzene alone (p < 0.05).
June 1981 33Table 4. Effect of partial hepatectomy on erythrocyte 5SFe utilization and urinary metabolites of benzene in rats after a single
injection of benzene.
Sham operationa Partial hepatectomya
Erythrocyte 59Fe utilization, %b
Control (olive oil) 31.6 ± 13.3 (9)b 29.1 ± 6.5 (10)
Benzene (2200 mg/kg, SC) 15.4 ± 6.7 (10)C 36.4 ± 16.2 (10)
Urinary metabolites, benzene equivalent, p.mold
[3H] Benzene (2200 mg/kg, SC) 132.2 ± 52.2 (4) 40.5 ± 19.8 (5)C
aMean ± SD: the number of animals is given in parentheses.
bBased on administered dose: 24 hr 59Fe uptake was measured 48 hr after benzene administration.
CSignificantly different from control sham-operated rats (p < 0.01) and from benzene-treated partially hepatectomized rats (p <
0.01).
dMeasured as 36 hr cumulative urinary radioactivity.
Table 5. Effect ofpentobarbital on the action ofmultiple doses ofcytarabine on the '9Fe uptake measured 48 hr aftertreatment.
24 hr 59Fe uptake at various doses of cytarabine (mean + SD), %a
Groups 25 mg/kg x 3b 20 mg/kg x 3b 100 mg/kg x 3b
Control, saline 20.5 ± 8.9 (16) 19.8 ± 3.6 (16) 21.1 ± 3.9 (19)
Pentobarbitalc 20.5 + 5.2 (18) 20.7 ± 5.2 (17) 20.7 ± 5.8 (13)
Cytarabine 13.2 ± 4.7 (16) 6.6 ± 4.0 (17) 3.1 + 1.5 (18)
Pentobarbitald + cytarabine 16.1 ± 5.4 (22) 11.8 ± 4.0e (21) 6.9 ± 2.8e (17)
aNumber of mice given in parentheses.
bThree doses were given at 2 hr intervals. The 24 hr °9Fe uptake was measured 48 hr after the last dose of cytarabine.
cTwo or three successive doses of 60 mg/kg to maintain anesthesia for 6 hr.
dPentobarbital (60 mg/kg) was given 1 hr prior to cytarabine and anesthesia was maintained for 6 hr by 1 or 2 additional dose(s) of
pentobarbital.
eSignificantly higher than the value of cytarabine treated group (p < 0.001).
(36-38) and cytotoxic agents (39), the effect of
pentobarbital on the cytotoxic action of cytarabine
and hydroxyurea to erythrocytic progenitors (pro-
normoblasts) and hemopoietic stem cells in cell
cycle were investigated using the 59Fe uptake
method.
Data in Table 5 show that pentobarbital alone
had no effect on pronormoblasts, while cytarabine
given in three doses of25, 50, or 100 mg/kg every 2
hr produced dose-dependent damage on pronor-
moblasts. When pentobarbital was given 1 hr prior
to cytarabine and anesthesia was maintained until 1
hr following the last dose of cytarabine, the inhibi-
tion of 59Fe uptake by cytarabine was significantly
reduced at 50 and 100 mg/kg x 3, indicating that
pentobarbital alleviated the toxicity of cytarabine
on proliferating erythroid cells. Similar results
were also obtained with hydroxyurea (Table 6).
Experimental results of pentobarbital action on
the proliferating hemopoietic stem cells challenged
with hydroxyurea is shown in Table 7. Here also,
pentobarbital alone had no effect on the stem cells.
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Table 6. Effect of pentobarbital on the action of multiple
doses ofhydroxyurea on the 59Fe uptake measured 48 hr after
treatment.
24 hr 59Fe uptake
Group (mean ± SD), %a,b
Control, saline 40.6 ± 9.0 (15)
Pentobarbitalc 37.9 ± 9.5 (13)
Hydroxyuread
167 mg/kg x 3 12.6 ± 3.9 (12)
333 mg/kg x 3 6.5 ± 2.8 (10)
Pentobarbital + hydroxyureae
167 mg/kg x 3 23.3 ± 7.3f (16)
333 mg/kg x 3 17.5 ± 4.7f (15)
"9Fe was given IV.
bNumber of mice given in parentheses.
cTwo or three successive doses of 60 mg/kg to maintain
anesthesia for 6 hr.
dThree doses were given at 2 hr intervals. The 59Fe uptake
was measured 48 hr after the last dose of cytarabine.
'Pentobarbital (60mg/kg) was given 30min prior to hydroxyurea
and anesthesia was maintained for 6 hr by 1 or 2 additional
dose(s) of pentobarbital.
fSignificantly higher than the value of hydroxyurea treated
group (p < 0.001).
Environmental Health PerspectivesTable 7. Effect of pentobarbital on the action of hydroxyurea on the "9Fe uptake measured 72 hr after treatment.
24 hr 59Fe uptake
Group Schedule of administration (mean + SD) %a.b
Control Saline, 0.1 m three times at 2 hr intervals 34.1 + 6.4 (13)
Pentobarbital Two or three doses of 60 mg/kg to keep anesthesia for 6 hr 38.5 + 9.5 (9)
Hydroxyurea
Schedule A Three successive doses of 500 mg/kg at 2 hr intervals 35.9 ± 7.7 (9)
Schedule B Initial dose (2000 mg/kg) 12 hr prior to three doses of 11.5 ± 5.2c (10)
500 mg/kg every 2 hr
Pentobarbital + hydroxyurea Hydroxyurea given by schedule B and pentobarbital given 22.8 + 5.4d (10)
(schedule B) 30 min prior to 3 doses of hydroxyurea for 6 hr
a9Fe was given IV
bNumber of mice given in parentheses.
CSignificantly lower than control values (p < 0.001).
dSignificantly higher than the value of hydroxyurea treated (schedule B) group (p < 0.001).
Table 8. Effect of pentobarbital on the action of cytarabine on the "9Fe uptake measured 72 hr after treatment.
24 hr 59Fe uptakea
Groups Schedule of administration Mean + SD, So% % of control
Saline, 0.1 ml three times at 2 hr intervals
Control Two or three successive doses of 60 mg/kg to 23.2 ± 6.8 (10) 100.0
Pentobarbital maintain anesthesia for 6 hr 23.4 + 4.4 (10) 100.9
Cytarabine Three successive doses of 150 mg/kg every 2 hr
Schedule A Initial dose (150 mg/kg) 12 hr prior to three suc- 22.4 + 7.2 (8) 96.6
Schedule B cessive doses of 100 mg/kg every 2 hr 3.9 + 3.8(100) 16.8
Cytarabine given by schedule B and pento-
Pentobarbitalb + cytarabine barbital given 1 hr prior to three successive doses 15.4 + 3.3'"(10) 66.4
(schedule B) of cytarabine
aNumber of mice given in parentheses.
bPentobarbital anesthesia was maintained for 6 hr by two or three successive doses of 60 mg/kg.
"Significantly lower than control values (p < 0.001).
dSignificantly higher than the value of cytarabine treated group (p < 0.001).
Hydroxyurea, which is also a S-phase specific agent
(16, 40, 41), did not affect the 59Fe uptake when the
stem cells are in Go. However, when an initial dose
ofhydroxyurea (2000 mg/kg) was given 12 hr prior
to three successive doses of hydroxyTurea (500
mg/kg every 2 hr, schedule A), the 5 Fe uptake
value was reduced to 32% of the hydroxyurea
treated group given schedule A alone. Several
groups of investigators have independently shown
that an initial dose of hydroxyurea activated Go
stem cells into cell cycle on the basis ofthe CFU-S
assay (11, 42, 43). Thus, the present data confirms
that the S-phase specific agent, hydroxyurea, can
only kill the proliferating cells whether they are
stem cells or pronormoblasts but it can not kill cells
in the Go state such as resting hemopoietic stem
cells. When pentobarbital is given 30 min prior to
the three successive doses of hydroxyurea follow-
ing an activation of Go stem cells, the 59Fe uptake
value was increased twofold. This protective effect
ofpentobarbital on proliferating stem cells was also
observed when they were insulted with cytarabine
(Table 8). The mechanism by which pentobarbital
protects proliferating hemopoietic cells from cytot-
oxic agents remains to be seen. In summary, the
proper application offerrokinetics and other devel-
opmental characteristics of erythropoietic cells en-
ables the establishment ofamethodology which can
be used to estimate the potential toxic effect of
chemicals on erythropoietic cells and pluripotent
hemopoietic stem cells.
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